AU2014361798B2 - Methods to treat lymphoplasmacytic lymphoma - Google Patents
Methods to treat lymphoplasmacytic lymphoma Download PDFInfo
- Publication number
- AU2014361798B2 AU2014361798B2 AU2014361798A AU2014361798A AU2014361798B2 AU 2014361798 B2 AU2014361798 B2 AU 2014361798B2 AU 2014361798 A AU2014361798 A AU 2014361798A AU 2014361798 A AU2014361798 A AU 2014361798A AU 2014361798 B2 AU2014361798 B2 AU 2014361798B2
- Authority
- AU
- Australia
- Prior art keywords
- certain embodiments
- optionally substituted
- alkyl
- group
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CCN1CC*(Cc(c(C(F)(F)F)c2)ccc2NC(c2cc(OC3=CC(NC4CNC4)NC=N3)c(C)cc2)=O)CC1 Chemical compound CCN1CC*(Cc(c(C(F)(F)F)c2)ccc2NC(c2cc(OC3=CC(NC4CNC4)NC=N3)c(C)cc2)=O)CC1 0.000 description 18
- QWQFGTOJXBOYJO-HYXAFXHYSA-N C/C=C(/C(N1)=O)\SC1=C Chemical compound C/C=C(/C(N1)=O)\SC1=C QWQFGTOJXBOYJO-HYXAFXHYSA-N 0.000 description 1
- YRNYCYKPEAJOBQ-HYXAFXHYSA-N CC(C)/C=C(/C(N1)=O)\SC1=N Chemical compound CC(C)/C=C(/C(N1)=O)\SC1=N YRNYCYKPEAJOBQ-HYXAFXHYSA-N 0.000 description 1
- BDRXIHMSZOYUAN-UHFFFAOYSA-N CC(C)C(N1CCN(C)CC1)=O Chemical compound CC(C)C(N1CCN(C)CC1)=O BDRXIHMSZOYUAN-UHFFFAOYSA-N 0.000 description 1
- UJTKZASSWFSFJS-UHFFFAOYSA-N CC(C)NC(CCN(CC1)CCN1C(OC(C)(C)C)=O)=O Chemical compound CC(C)NC(CCN(CC1)CCN1C(OC(C)(C)C)=O)=O UJTKZASSWFSFJS-UHFFFAOYSA-N 0.000 description 1
- BUCKQURJUDIRKS-UHFFFAOYSA-N CC(C)Nc1ncnc(NCCN2CCCC2)c1 Chemical compound CC(C)Nc1ncnc(NCCN2CCCC2)c1 BUCKQURJUDIRKS-UHFFFAOYSA-N 0.000 description 1
- NOVYSIQVVWXHGB-UHFFFAOYSA-N CCC(Nc1cc(Oc2c(C)ccc(C(Nc3ccc(CN4CCN(CC)CC4)c(C(F)(F)F)c3)=O)c2)ncn1)=O Chemical compound CCC(Nc1cc(Oc2c(C)ccc(C(Nc3ccc(CN4CCN(CC)CC4)c(C(F)(F)F)c3)=O)c2)ncn1)=O NOVYSIQVVWXHGB-UHFFFAOYSA-N 0.000 description 1
- FIBFTUNTEWACAK-UHFFFAOYSA-N CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2NC(c2cc(Oc3cc(NC4CNC4)ncn3)c(C)cc2)=O)CC1 Chemical compound CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2NC(c2cc(Oc3cc(NC4CNC4)ncn3)c(C)cc2)=O)CC1 FIBFTUNTEWACAK-UHFFFAOYSA-N 0.000 description 1
- IKQXHPDWGQELDU-UHFFFAOYSA-N CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2NC(c2cc(Oc3cc(NN(C)C)ncn3)c(C)cc2)=O)CC1 Chemical compound CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2NC(c2cc(Oc3cc(NN(C)C)ncn3)c(C)cc2)=O)CC1 IKQXHPDWGQELDU-UHFFFAOYSA-N 0.000 description 1
- KBCFGUGFJSFWKD-UHFFFAOYSA-N CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2NC(c2cc(Oc3cc(Nc4cncnc4)ncn3)c(C)cc2)=O)CC1 Chemical compound CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2NC(c2cc(Oc3cc(Nc4cncnc4)ncn3)c(C)cc2)=O)CC1 KBCFGUGFJSFWKD-UHFFFAOYSA-N 0.000 description 1
- BMPXPANSAQOTAY-UHFFFAOYSA-N CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2NC(c2cc(Oc3nc(Nc4c[o]nc4)ncc3)c(C)cc2)=O)CC1 Chemical compound CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2NC(c2cc(Oc3nc(Nc4c[o]nc4)ncc3)c(C)cc2)=O)CC1 BMPXPANSAQOTAY-UHFFFAOYSA-N 0.000 description 1
- GJAQIFQPFSPOOM-UHFFFAOYSA-N CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2NC(c2cc(Oc3ncnc(NC(C4CC4)=O)c3)c(C)cc2)=O)CC1 Chemical compound CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2NC(c2cc(Oc3ncnc(NC(C4CC4)=O)c3)c(C)cc2)=O)CC1 GJAQIFQPFSPOOM-UHFFFAOYSA-N 0.000 description 1
- FCNPQYHKUYSELK-UHFFFAOYSA-N CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2NC(c2cc(Oc3ncnc(NC)c3)c(C)cc2)=O)CC1 Chemical compound CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2NC(c2cc(Oc3ncnc(NC)c3)c(C)cc2)=O)CC1 FCNPQYHKUYSELK-UHFFFAOYSA-N 0.000 description 1
- IVMXZQAMEUPQFS-UHFFFAOYSA-N CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2NC(c2ccc(C)c(Oc3cc(Nc4n[n](C)cc4)ncn3)c2)=O)CC1 Chemical compound CCN1CCN(Cc(c(C(F)(F)F)c2)ccc2NC(c2ccc(C)c(Oc3cc(Nc4n[n](C)cc4)ncn3)c2)=O)CC1 IVMXZQAMEUPQFS-UHFFFAOYSA-N 0.000 description 1
- INGLCIWCZSLENQ-UHFFFAOYSA-N CCN1CCN(Cc(cc2)c(C(F)(F)F)cc2NC(c2cc(Oc3cc(Nc4c[nH]nc4)ncn3)c(C)cc2)=O)CC1 Chemical compound CCN1CCN(Cc(cc2)c(C(F)(F)F)cc2NC(c2cc(Oc3cc(Nc4c[nH]nc4)ncn3)c(C)cc2)=O)CC1 INGLCIWCZSLENQ-UHFFFAOYSA-N 0.000 description 1
- WGCYRFWNGRMRJA-UHFFFAOYSA-N CCN1CCNCC1 Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 1
- HVPWCXPBVJEMKK-UHFFFAOYSA-N CNNC(C=C)=O Chemical compound CNNC(C=C)=O HVPWCXPBVJEMKK-UHFFFAOYSA-N 0.000 description 1
- BLHTXORQJNCSII-UHFFFAOYSA-N Cc1c[n](C)cn1 Chemical compound Cc1c[n](C)cn1 BLHTXORQJNCSII-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N Cc1ccccn1 Chemical compound Cc1ccccn1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- QMNUDYFKZYBWQX-UHFFFAOYSA-N O=C1NC=Nc2c1cccc2 Chemical compound O=C1NC=Nc2c1cccc2 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N c1cc2ccccc2cc1 Chemical compound c1cc2ccccc2cc1 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N c1ccc2ncncc2c1 Chemical compound c1ccc2ncncc2c1 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915684P | 2013-12-13 | 2013-12-13 | |
| US61/915,684 | 2013-12-13 | ||
| US201462036934P | 2014-08-13 | 2014-08-13 | |
| US62/036,934 | 2014-08-13 | ||
| PCT/US2014/070162 WO2015089479A1 (en) | 2013-12-13 | 2014-12-12 | Methods to treat lymphoplasmacytic lymphoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014361798A1 AU2014361798A1 (en) | 2016-06-09 |
| AU2014361798B2 true AU2014361798B2 (en) | 2020-06-11 |
Family
ID=53371894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014361798A Ceased AU2014361798B2 (en) | 2013-12-13 | 2014-12-12 | Methods to treat lymphoplasmacytic lymphoma |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9856223B2 (OSRAM) |
| EP (1) | EP3079683A4 (OSRAM) |
| JP (1) | JP6879740B2 (OSRAM) |
| AU (1) | AU2014361798B2 (OSRAM) |
| CA (1) | CA2932351A1 (OSRAM) |
| WO (1) | WO2015089479A1 (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9908872B2 (en) | 2013-12-13 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| AU2014361798B2 (en) | 2013-12-13 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| EP3715346B1 (en) | 2014-10-22 | 2024-01-03 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
| EP3236959B1 (en) | 2014-12-23 | 2025-09-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CA2978518C (en) | 2015-03-27 | 2023-11-21 | Nathanael S. Gray | Inhibitors of cyclin-dependent kinases |
| EP3313530B1 (en) * | 2015-06-26 | 2022-10-05 | Dana Farber Cancer Institute, Inc. | 4,6-pyrimidinylene derivatives and uses thereof |
| CA3015417A1 (en) | 2016-03-01 | 2017-09-08 | Propellon Therapeutics Inc. | Inhibitors of wdr5 protein-protein binding |
| JP7624690B2 (ja) | 2016-03-01 | 2025-01-31 | プロペロン セラピューティクス インコーポレイテッド | Ｗｄｒ５タンパク質－タンパク質結合の阻害剤 |
| UA125650C2 (uk) | 2016-09-09 | 2022-05-11 | Інсайт Корпорейшн | Регулятори нрk1 на основі похідних піразолопіридину та їх застосування для лікування раку |
| US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| AR109595A1 (es) * | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 |
| EP3573618B1 (en) | 2017-01-30 | 2023-08-16 | The Children's Hospital of Philadelphia | Compositions and methods for hemoglobin production |
| US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| WO2018228920A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| WO2018228923A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases |
| WO2018228925A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| CN109180677A (zh) * | 2017-06-30 | 2019-01-11 | 厦门大学 | 取代芳基醚类化合物、其制备方法、药用组合物及其应用 |
| EP3655406A1 (en) | 2017-07-18 | 2020-05-27 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| WO2019051199A1 (en) * | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS |
| EP3752504A4 (en) | 2018-02-14 | 2021-06-09 | Dana Farber Cancer Institute, Inc. | IRAQ DEGRADER AND USES THEREOF |
| HRP20220833T1 (hr) | 2018-02-20 | 2022-10-28 | Incyte Corporation | Derivati n-(fenil)-2-(fenil)pirimidin-4-karboksamida i odgovarajući spojevi kao inhibitori hpk1 za liječenje raka |
| WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| WO2020005807A1 (en) | 2018-06-25 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| KR102545594B1 (ko) | 2018-07-31 | 2023-06-21 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제 |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| TW202028207A (zh) | 2018-09-25 | 2020-08-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
| WO2020120257A1 (en) | 2018-12-11 | 2020-06-18 | Bayer Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| EP3902542A4 (en) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| MX2022001562A (es) | 2019-08-06 | 2022-04-26 | Incyte Corp | Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1). |
| WO2021249913A1 (en) | 2020-06-09 | 2021-12-16 | Bayer Aktiengesellschaft | 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer |
| EP4288437A1 (en) | 2021-02-05 | 2023-12-13 | Bayer Aktiengesellschaft | Map4k1 inhibitors |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010026095A1 (de) * | 2008-09-02 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Neue benzamide, deren herstellung und deren verwendung als arzneimittel |
| WO2011028995A1 (en) * | 2009-09-03 | 2011-03-10 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| WO2011090738A2 (en) * | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| WO2015069287A1 (en) * | 2013-11-08 | 2015-05-14 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9816837D0 (en) | 1998-08-04 | 1998-09-30 | Zeneca Ltd | Amide derivatives |
| ATE269295T1 (de) | 1998-04-17 | 2004-07-15 | Parker Hughes Inst | Btk inhibitoren und verfahren zur identifizierung und verwendung |
| BR9912729A (pt) | 1998-08-04 | 2001-05-02 | Astrazeneca Ab | Derivado de amida, processo para prepará-lo, e, uso do mesmo |
| AU761361B2 (en) | 1998-09-25 | 2003-06-05 | Astrazeneca Ab | Benzamide derivatives and their use as cytokine inhibitors |
| US6306897B1 (en) | 1999-03-19 | 2001-10-23 | Parker Hughes Institute | Calanolides for inhibiting BTK |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| PT1212327E (pt) | 1999-09-17 | 2004-01-30 | Abbott Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos |
| ATE511840T1 (de) | 2001-10-09 | 2011-06-15 | Amgen Inc | Imidazolderivate als entzündungshemmende mittel |
| RU2005106871A (ru) | 2002-08-14 | 2005-10-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Ингибиторы протеинкиназ и их применение |
| PT1913952E (pt) | 2002-12-05 | 2011-04-14 | Univ Arkansas | Determinantes moleculares da doença óssea do mieloma e respectivas utilizações |
| ES2571779T3 (es) | 2002-12-13 | 2016-05-26 | Ym Biosciences Australia Pty | Inhibidores de cinasa a base de nicotinamida |
| US20070281907A1 (en) | 2003-12-22 | 2007-12-06 | Watkins William J | Kinase Inhibitor Phosphonate Conjugates |
| TW200616974A (en) | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| PE20060664A1 (es) | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
| CA2590750A1 (en) | 2004-12-20 | 2006-06-29 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Myd88 homodimerization inhibitors |
| CA2589773A1 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Pyridine carboxamide derivatives for use as anticancer agents |
| WO2006067445A2 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
| CA2593803A1 (en) | 2005-01-26 | 2006-08-03 | Irm Llc | Thiazole-amide compounds and compsitions as protein kinase inhibitors |
| US7605154B2 (en) | 2005-08-08 | 2009-10-20 | Janssen Pharmaceutica N.V. | Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors |
| US7754717B2 (en) | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| GT200600411A (es) | 2005-09-13 | 2007-05-21 | Novartis Ag | Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular |
| JP5225857B2 (ja) | 2005-11-14 | 2013-07-03 | ジェネンテック，インコーポレイティド | ヘッジホッグシグナル伝達のビスアミド阻害剤 |
| AU2006328194A1 (en) | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Quinazoline derivatives, process for their preparation and their use as anti-cancer agents |
| US20070155746A1 (en) * | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases |
| GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
| US20090312396A1 (en) * | 2006-07-10 | 2009-12-17 | Astrazeneca Ab | Methods for cancer treatment using tak1 inhibitors |
| EP2526934B1 (en) | 2006-09-22 | 2015-12-09 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| SG178712A1 (en) | 2006-10-02 | 2012-03-29 | Medarex Inc | Human antibodies that bind cxcr4 and uses thereof |
| US20120065201A1 (en) | 2007-03-28 | 2012-03-15 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| BRPI0810028A2 (pt) | 2007-04-17 | 2014-10-21 | Novartis Ag | Éteres de amidas de ácido naftaleno carboxílico no tratamento de câncer |
| WO2008144253A1 (en) | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| TW200906825A (en) | 2007-05-30 | 2009-02-16 | Scripps Research Inst | Inhibitors of protein kinases |
| TW200911798A (en) | 2007-08-02 | 2009-03-16 | Amgen Inc | PI3 kinase modulators and methods of use |
| US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| JP5600063B2 (ja) * | 2007-10-19 | 2014-10-01 | セルジーン アビロミクス リサーチ， インコーポレイテッド | ヘテロアリール化合物およびその使用 |
| KR20120033357A (ko) | 2007-10-23 | 2012-04-06 | 테바 파마슈티컬 인더스트리즈 리미티드 | 다사티닙 다형체 및 이의 제조 방법 |
| US8394816B2 (en) | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
| WO2009076373A1 (en) | 2007-12-10 | 2009-06-18 | Concert Pharmaceuticals Inc. | Heterocyclic kinase inhibitors |
| WO2009137596A1 (en) | 2008-05-06 | 2009-11-12 | Cgi Pharmaceuticals, Inc. | Substituted amides, method of making, and use as btk inhibitors |
| EP2361248B1 (en) | 2008-06-27 | 2018-09-19 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| US7824861B2 (en) | 2008-07-10 | 2010-11-02 | National Tsing Hua University | Method for quantitative analysis of transcripts with nucleotide polymorphism at specific site |
| DK2319830T3 (en) | 2008-08-13 | 2017-02-13 | Mitsui Chemicals Agro Inc | Amide derivative, pesticide containing the amide derivative and use of the pesticide |
| WO2010056875A1 (en) | 2008-11-12 | 2010-05-20 | Cgi Pharmaceuticals, Inc. | Pyridazinones and their use as btk inhibitors |
| KR101596539B1 (ko) | 2008-12-23 | 2016-02-22 | 제넨테크, 인크. | 암 환자에서의 진단 목적용 방법 및 조성물 |
| EP2485589A4 (en) | 2009-09-04 | 2013-02-06 | Biogen Idec Inc | HETEROARYL-BTK INHIBITORS |
| CN102918042B (zh) | 2010-02-08 | 2016-03-09 | 默沙东有限责任公司 | 8-甲基-1-苯基-咪唑[1,5-a]吡嗪化合物 |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| KR101995013B1 (ko) | 2010-07-13 | 2019-07-02 | 에프. 호프만-라 로슈 아게 | Irak4 조절제로서 피라졸로[1,5a]피리미딘 및 티에노[3,2b]피리미딘 유도체 |
| WO2012062704A1 (en) | 2010-11-09 | 2012-05-18 | Cellzome Limited | Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
| WO2012068096A2 (en) | 2010-11-15 | 2012-05-24 | Exelixis, Inc. | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture |
| PL2714677T3 (pl) | 2011-05-23 | 2019-02-28 | Merck Patent Gmbh | Pochodne pirydynowe i pirazynowe |
| KR20180084153A (ko) | 2011-06-10 | 2018-07-24 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법 |
| US10465247B2 (en) | 2011-07-01 | 2019-11-05 | Dana-Farber Cancer Institute, Inc. | Discovery of a somatic mutation in MYD88 gene in lymphoplasmacytic lymphoma |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| EP2763966B1 (en) | 2011-10-03 | 2018-04-04 | Syngenta Participations AG | Insecticidal 2-methoxybenzamide derivatives |
| CA2850763A1 (en) | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
| SG11201401993RA (en) | 2011-11-03 | 2014-05-29 | Hoffmann La Roche | Alkylated piperazine compounds as inhibitors of btk activity |
| RS58102B1 (sr) | 2011-11-09 | 2019-02-28 | Bristol Myers Squibb Co | Lečenje hematoloških maligniteta sa anti-cxcr4 antitelom |
| WO2013074986A1 (en) | 2011-11-17 | 2013-05-23 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| CA2857302C (en) | 2011-12-15 | 2020-08-25 | Novartis Ag | Use of inhibitors of the activity or function of pi3k |
| JP6327713B2 (ja) | 2012-07-27 | 2018-05-23 | 国立研究開発法人理化学研究所 | 急性骨髄性白血病の治療又は再発抑制剤 |
| CN103405429A (zh) | 2013-08-22 | 2013-11-27 | 中国药科大学 | 一类vegfr-2抑制剂及其用途 |
| WO2015038887A1 (en) | 2013-09-12 | 2015-03-19 | Dana-Farber Cancer Institute Inc. | Methods for evaluating and treating waldenstrom's macroglobulinemia |
| WO2015085075A1 (en) | 2013-12-06 | 2015-06-11 | Dana-Farber Cancer Institute, Inc. | Methods to distinguish waldenström's macroglobulinemia from igm monoclonal gammopathy of undetermined significance |
| US9908872B2 (en) | 2013-12-13 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| AU2014361798B2 (en) | 2013-12-13 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| WO2016055982A1 (en) | 2014-10-10 | 2016-04-14 | Acerta Pharma B.V. | Quinoline and quinazoline compounds |
| EP3715346B1 (en) | 2014-10-22 | 2024-01-03 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
| WO2017172826A1 (en) | 2016-03-28 | 2017-10-05 | Presage Biosciences, Inc. | Pharmaceutical combinations for the treatment of cancer |
| JP2019518006A (ja) | 2016-04-29 | 2019-06-27 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｍｙｄ８８変異型疾患における治療標的としてのｈｃｋ |
| CN106008371A (zh) | 2016-06-24 | 2016-10-12 | 谢阳 | 1-芳基脲基环烷基-1-甲酰胺类化合物及其药物组合物和应用 |
| CN106279120A (zh) | 2016-07-15 | 2017-01-04 | 谢阳 | 一种n‑芳基氨基甲酰基脯氨酸类化合物及其药物组合物和应用 |
| CN107056786B (zh) | 2016-10-14 | 2019-05-07 | 苏州明锐医药科技有限公司 | 阿卡替尼的制备方法 |
| JP2021506735A (ja) | 2017-05-26 | 2021-02-22 | イクノス サイエンシズ エスエー | 新規ｍａｐ４ｋ１阻害剤 |
| US20230058545A1 (en) | 2019-10-08 | 2023-02-23 | Dana-Farber Cancer Institute, Inc. | Hck as a therapeutic target in myd88 mutated diseases |
| CN114746095B (zh) | 2019-10-08 | 2025-01-24 | 达纳-法伯癌症研究所有限公司 | Hck作为myd88突变疾病的治疗靶点 |
-
2014
- 2014-12-12 AU AU2014361798A patent/AU2014361798B2/en not_active Ceased
- 2014-12-12 JP JP2016539113A patent/JP6879740B2/ja active Active
- 2014-12-12 EP EP14869964.8A patent/EP3079683A4/en not_active Withdrawn
- 2014-12-12 WO PCT/US2014/070162 patent/WO2015089479A1/en not_active Ceased
- 2014-12-12 CA CA2932351A patent/CA2932351A1/en not_active Abandoned
- 2014-12-12 US US15/104,132 patent/US9856223B2/en not_active Ceased
- 2014-12-12 US US17/534,896 patent/USRE50030E1/en active Active
-
2017
- 2017-12-19 US US15/847,430 patent/US10633348B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010026095A1 (de) * | 2008-09-02 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Neue benzamide, deren herstellung und deren verwendung als arzneimittel |
| WO2011028995A1 (en) * | 2009-09-03 | 2011-03-10 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| WO2011090738A2 (en) * | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| WO2015069287A1 (en) * | 2013-11-08 | 2015-05-14 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
Non-Patent Citations (5)
| Title |
|---|
| CAS RN 1240194-14-2, STN Entry Date 07 Sep 2010 * |
| CAS RN 1348855-14-0, STN Entry Date 05 Dec 2011 * |
| CAS RN 1359387-63-5, STN Entry Date 02 Mar 2012 * |
| CAS RN 1359510-63-6, STN Entry Date 02 Mar 2012 * |
| Li, S. et al, "Synthesis and biological evaluation of 4-[3-chloro-4-(3-fluorobenzyloxy_anilino]-6-3-substituted-phenoxy)pyrimidines and dual EGFR/ErbB-2 kinase inhibitors", Bioorganic & Medicinal Chemistry, 2012, 20, 877-885 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3079683A4 (en) | 2017-12-20 |
| AU2014361798A1 (en) | 2016-06-09 |
| JP2017502006A (ja) | 2017-01-19 |
| USRE50030E1 (en) | 2024-07-02 |
| EP3079683A1 (en) | 2016-10-19 |
| US20180194739A1 (en) | 2018-07-12 |
| WO2015089479A1 (en) | 2015-06-18 |
| US20160318878A1 (en) | 2016-11-03 |
| US10633348B2 (en) | 2020-04-28 |
| US9856223B2 (en) | 2018-01-02 |
| JP6879740B2 (ja) | 2021-06-02 |
| CA2932351A1 (en) | 2015-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014361798B2 (en) | Methods to treat lymphoplasmacytic lymphoma | |
| JP7200282B2 (ja) | サイクリン依存性キナーゼの阻害剤 | |
| AU2014361800B2 (en) | Methods to treat lymphoplasmacytic lymphoma | |
| AU2015292827B2 (en) | Macrocyclic kinase inhibitors and uses thereof | |
| AU2015292818B2 (en) | Imidazolyl kinase inhibitors and uses thereof | |
| AU2017291812B2 (en) | Bicyclic urea kinase inhibitors and uses thereof | |
| US10844077B2 (en) | Thiazolyl-containing compounds for treating proliferative diseases | |
| AU2016283105A1 (en) | 4,6-pyrimidinylene derivatives and uses thereof | |
| WO2014063054A1 (en) | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof | |
| CA2996978A1 (en) | Inhibitors of cyclin-dependent kinases | |
| AU2016283100A1 (en) | Fused bicyclic pyrimidine derivatives and uses thereof | |
| AU2020357983B2 (en) | Tricyclic kinase inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |